The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Novartis and “Drop the Case”: defending a key source of generic drugs India is sometimes called “the pharmacy of the developing world,” because it manufactures so many affordable generic medicines relied on by millions of people around ...